Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Leuk Lymphoma. 2016 Aug 11;58(4):923–931. doi: 10.1080/10428194.2016.1213823

Figure 1.

Figure 1.

Ganetespib kills EBV-positive and EBV-negative cells lines in a dose-dependent manner. A. EBV-positive (LCLa, LCLb, Akata, Kem I, Mutu I) and EBV-negative (BJAB, BL30) cells were treated with increasing concentrations of ganetespib for 72 hr and cell viability was measured using alamarBlue. A representative experiment is shown in which each point represents the mean of triplicate replicates. B. EBV-positive (SNT16) and EBV-negative (Jurkat) cells were treated as in panel A. The experiment was repeated twice and a representative result is shown. C. Freshly isolated human PBMCs from different donors were treated with increasing concentrations of ganetespib for 72 hr and cell viability was analyzed by trypan blue staining. Trypan blue staining was used to measure viability of PBMCs since the cells did not have sufficient metabolic activity to metabolize alamarBlue. The experiment was repeated twice with a total of 4 different donors and similar results were observed.